Susquehanna Fundamental Investments LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)

Susquehanna Fundamental Investments LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 44,785 shares of the biotechnology company's stock, valued at approximately $593,000. Susquehanna Fundamental Investments LLC owned approximately 0.15% of AnaptysBio at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in shares of AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,531 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of AnaptysBio in the fourth quarter valued at about $40,000. AlphaQuest LLC increased its stake in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC raised its position in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in AnaptysBio by 1,585.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after buying an additional 5,360 shares in the last quarter.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.20 during trading hours on Friday, reaching $19.38. 163,083 shares of the company's stock were exchanged, compared to its average volume of 914,666. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $41.31. The company has a market cap of $573.14 million, a P/E ratio of -3.19 and a beta of -0.20. The company's 50 day moving average is $18.55 and its two-hundred day moving average is $18.81.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a share buyback program on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ANAB. Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Thursday, May 1st. Guggenheim raised their target price on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday. Wolfe Research started coverage on AnaptysBio in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price target for the company. Wells Fargo & Company lifted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Finally, HC Wainwright restated a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.88.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.